Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01799473 · ClinicalTrials.gov registry record
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
A clinical trial, sponsored by United Therapeutics.
- Completed
- Registry status
- 98
- Enrollment target
NCT01799473: Completed study, sponsored by United Therapeutics.
NCT01799473 is a clinical trial that has completed, run by United Therapeutics. The registered enrollment target is 98 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01799473 has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
Study Summary
This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH). Once enrolled, the patients' dose and titration will be followed for the first 6 months of treatment with Tyvaso. A call-center will contact the patients directly at weeks 1, 2, 3, 4, 8, 12, 16, 20, and 24 to review their dose and titration schedule. In addition to patient-reported dosing data, some patient demographic information, will be collected by the investigative site at Baseline.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-12 |
What the finished NCT01799473 record still lists
NCT01799473 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01799473 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01799473 about?
NCT01799473 is a clinical study titled "Tyvaso Dosing and Titration Evaluation: TyTRATE Registry". This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH). Once enrolled, the patients' dose and titration will be followed for the first 6 months of treatment with Tyvaso. A call...
What is the current status of trial NCT01799473?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2013-01. Estimated completion is 2014-12.
Who is sponsoring clinical trial NCT01799473?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia